EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Characterizing the association of heparin dose and activated clotting time on lower extremity bypass outcomes

Craig S Brown, Shukri Dualeh, Nicholas H Osborne, Jeremy Albright, Andrew Huang, Loay Kabbani, Frank M Davis, Herbert D Aronow, Andrew S Kimball, Eugene Laveroni, Paul Bove, Constantinos Constantinou und 2 weitere

Journal of Vascular Surgery · 2026

DOI: 10.1016/j.jvs.2026.05.014 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Vascular Surgery, 2026. Verfasst von Craig S Brown und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Section of Vascular Surgery, University of Michigan, Ann Arbor, MI; Center for Healthcare Outcomes and Policy, Institute for H…. Hauptthemen laut MEDLINE: Anticoagulants, Blood Coagulation, Graft Occlusion, Vascular, Heparin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anticoagulation is essential for preventing vascular thrombotic complications after vascular occlusive control. The effects of heparin dosing or monitoring activated clotting time (ACT) on postoperative outcomes remain poorly characterized. METHODS: Using data from a statewide collaborative, we investigated the rates of postoperative bleeding, arterial/graft thrombosis, major amputation, readmission, and death among patients within 30 days after lower extremity bypass with vein. We used a Bayesian random-effects multivariable logistic regression model to investigate the association between heparin dosing, ACT monitoring, and the interaction effect of the two, allowing for patients to cluster within surgeons and surgeons to cluster within hospitals. RESULTS: A total of 10,040 patients undergoing lower extremity bypass with vein from 34 hospitals were included, among whom 215 (2.1%) experienced predischarge arterial/graft thrombosis, 167 (1.7%) postoperative bleeding, 950 (9.5%) 30-day amputation, 1132 (11.3%) 30-day readmission, and 51 (0.5%) 30-day mortality. Rates of ACT monitoring varied substantially across hospitals (12%-100%) with 4921 (49.1%) patients having ACT monitored. Heparin dose was not associated with postoperative thrombosis (odds ratio [OR], 0.88; 95% credible interval, 0.70-0.1.11), 30-day amputation (OR, 0.93; 95% credible interval, 0.81-1.05), or bleeding (OR, 0.99; 95% credible interval, 0.76-1.29). The administration of protamine was associated with reduced postoperative bleeding (OR, 0.51; 95% credible interval, 0.36-0.72). Achieving an ACT of >250 was not associated with postoperative bleeding, thrombosis, amputation, readmission, or mortality. Receiver operating characteristic curve analysis suggests that no ACT value is a reliable cutoff for any of the assessed outcomes. CONCLUSIONS: Heparin dose, intraoperative ACT monitoring, and achieving an ACT of >250 were not associated with any of the outcomes assessed. Furthermore, no ACT target reliably predicted any outcome on receiver operating characteristic curve analysis. Administering adequate heparin doses without ACT monitoring may provide equivalent outcomes without the associated costs and logistical challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsBlood CoagulationGraft Occlusion, VascularHeparinThrombosisVascular GraftingMonitoring, IntraoperativeAgedFemaleHumansMaleMiddle AgedAmputation, SurgicalBayes TheoremDatabases, FactualLower ExtremityPatient ReadmissionPeripheral Arterial DiseasePostoperative HemorrhagePredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeWhole Blood Coagulation TimeMichigan

Stichwörter der Autor:innen

Activated clotting timeArterial bypassHeparinInfrainguinalLower extremity bypass

Substanzen

AnticoagulantsHeparin

Autor:innen und Institutionen

  • Department of Surgery, Section of Vascular Surgery, University of Michigan, Ann Arbor, MI; Center for Healthcare Outcomes and Policy, Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI…
  • Department of Surgery, Section of Vascular Surgery, University of Michigan, Ann Arbor, MI; Center for Healthcare Outcomes and Policy, Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI.
  • Department of Surgery, Section of Vascular Surgery, University of Michigan, Ann Arbor, MI.
  • Division of Vascular Surgery, Department of Surgery, Henry Ford Hospital, Detroit, MI.
  • Division of Cardiovascular Medicine, Henry Ford Hospital, Michigan State University College of Human Medicine, Detroit, MI.
  • Vascular Surgery, Corewell Health, Farmington Hills, MI.

Zitieren

APA

Brown, C. S., Dualeh, S., Osborne, N. H., Albright, J., Huang, A., Kabbani, L., Davis, F. M., Aronow, H. D., Kimball, A. S., Laveroni, E., Bove, P., Constantinou, C., Mouawad, N. J., & Henke, P. K. (2026). Characterizing the association of heparin dose and activated clotting time on lower extremity bypass outcomes. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2026.05.014

Vancouver

Brown CS, Dualeh S, Osborne NH, Albright J, Huang A, Kabbani L, et al. Characterizing the association of heparin dose and activated clotting time on lower extremity bypass outcomes. Journal of Vascular Surgery. 2026. doi:10.1016/j.jvs.2026.05.014

BibTeX
@article{Brown2026,
  author = {Brown, Craig S and Dualeh, Shukri and Osborne, Nicholas H and Albright, Jeremy and Huang, Andrew and Kabbani, Loay and Davis, Frank M and Aronow, Herbert D and Kimball, Andrew S and Laveroni, Eugene and Bove, Paul and Constantinou, Constantinos and Mouawad, Nicolas J and Henke, Peter K},
  title = {Characterizing the association of heparin dose and activated clotting time on lower extremity bypass outcomes},
  journal = {Journal of Vascular Surgery},
  year = {2026},
  doi = {10.1016/j.jvs.2026.05.014}
}
Kostenlos starten →